SCHEMBL899641

SCHEMBL899641

O=COC1CC1.O=COC1CC1

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23081736 1.00 HPGD (0.33) HPGD
SCHEMBL98197 1.00
SCHEMBL10709604 0.97
SCHEMBL8456551 0.88
SCHEMBL11210270 0.87 ADH1A (0.35)
SCHEMBL96545 0.87
SCHEMBL9238 0.87
SCHEMBL13447535 0.87 HPGD (0.31) HPGD
SCHEMBL135661 0.86 CYP19A1 (0.30)
SCHEMBL12993363 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250391519-A1 CHEMICAL SYNTHESIS PLATFORM UNIV GLASGOW COURT (GB) 2025-12-25 US disclosed
US-12358868-B2 Chemical derivatives and methods for synthesizing and compounding chemical derivatives related to capsaicin palmitate and capsaicin prodrugs CHORDA PHARMA, INC. (US) 2025-07-15 US disclosed
US-20230406816-A1 CHEMICAL DERIVATIVES AND METHODS FOR SYNTHESIZING AND COMPOUNDING CHEMICAL DERIVATIVES RELATED TO CAPSAICIN PALMITATE AND CAPSAICIN PRODRUGS CHORDA PHARMA INC (US) 2023-12-21 US disclosed
US-11773055-B2 Chemical derivatives and methods for synthesizing and compounding chemical derivatives related to capsaicin palmitate and capsaicin prodrugs CHORDA PHARMA, INC. (US) 2023-10-03 US disclosed
CN-110872230-B Preparation method of 1- (trifluoromethyl) cyclopropane-1-carboxylic acid compound and intermediate thereof 浙江九洲药业股份有限公司 2023-07-28 CN disclosed
US-20220168259-A1 CHEMICAL DERIVATIVES AND METHODS FOR SYNTHESIZING AND COMPOUNDING CHEMICAL DERIVATIVES RELATED TO CAPSAICIN PALMITATE AND CAPSAICIN PRODRUGS CHORDA PHARMA, INC. 2022-06-02 US disclosed
CN-110872230-A Preparation method and intermediate of 1- (trifluoromethyl) cyclopropane-1-carboxylic acid compound 浙江九洲药业股份有限公司 2020-03-10 CN disclosed
CN-104870446-B Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors 内尔维阿诺医学科学有限公司 2019-08-13 CN disclosed
CN-109476940-A Active energy ray curable resin for printing ink, active energy ray curable ink composition, active energy ray curable ink and cured film 哈利玛化成株式会社 2019-03-15 CN disclosed
CN-108472242-A Pharmaceutical composition for treating cancer 埃克塞里艾克西斯公司 2018-08-31 CN disclosed
CN-106488768-A Methods of treating lung adenocarcinoma 埃克塞里艾克西斯公司 2017-03-08 CN disclosed
CN-104788372-A Deuterated cabozantinib derivative, preparation method and application thereof, and intermediate of deuterated cabozantinib derivative SHANGHAI SHENGKAO MEDICAL TECHNOLOGY CO LTD 2015-07-22 CN disclosed
US-20140066444-A1 Method of Treating Cancer EXELIXIS, INC. (US) 2014-03-06 US disclosed
US-20140057908-A1 Method of Treating Cancer EXELIXIS, INC. (US) 2014-02-27 US disclosed
EP-2621482-A1 DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES Exelixis, Inc. (US) 2013-08-07 EP disclosed
US-20130197230-A1 METHODS OF PREPARING QUINOLINE DERIVATIVES EXELIXIS, INC. 2013-08-01 US disclosed
WO-2012044574-A1 DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES EXELIXIS, INC. (US) 2012-04-05 WO disclosed
EP-2350011-A1 METHODS OF PREPARING QUINOLINE DERIVATIVES Exelixis, Inc. (US) 2011-08-03 EP disclosed
WO-2010056960-A1 METHODS OF PREPARING QUINOLINE DERIVATIVES EXELIXIS INC. (US) 2010-05-20 WO disclosed
US-4826773-A AMMONIUM MOLYBDATE; PHOTOMETRY HOFFMANN-LA ROCHE INC. (US) 1989-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130197230-A1 METHODS OF PREPARING QUINOLINE DERIVATIVES F12, RECQL, H1-2 HPGD 1608/4885
US-11773055-B2 Chemical derivatives and methods for synthesizing and compounding chemical derivatives related to capsaicin palmitate and capsaicin prodrugs HCAR2, HCAR3, TRPV1 HPGD 222/4885
US-12358868-B2 Chemical derivatives and methods for synthesizing and compounding chemical derivatives related to capsaicin palmitate and capsaicin prodrugs HCAR2, HCAR3, TRPV1 HPGD 222/4885
US-20140066444-A1 Method of Treating Cancer MET, HGF, ACP3 HPGD 2411/4885
US-20250391519-A1 CHEMICAL SYNTHESIS PLATFORM SET, CBS, COASY HPGD 3120/4885
US-20220168259-A1 CHEMICAL DERIVATIVES AND METHODS FOR SYNTHESIZING AND COMPOUNDING CHEMICAL DERIVATIVES RELATED TO CAPSAICIN PALMITATE AND CAPSAICIN PRODRUGS HCAR2, HCAR3, TRPV1 HPGD 222/4885
US-20230406816-A1 CHEMICAL DERIVATIVES AND METHODS FOR SYNTHESIZING AND COMPOUNDING CHEMICAL DERIVATIVES RELATED TO CAPSAICIN PALMITATE AND CAPSAICIN PRODRUGS HCAR2, HCAR3, TRPV1 HPGD 222/4885
US-20140057908-A1 Method of Treating Cancer MET, HGF, ACP3 HPGD 2411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.